Thrice-weekly glatiramer regulatory update

Momenta said FDA accepted for review an ANDA for a generic version of thrice-weekly Copaxone glatiramer to treat relapsing forms of multiple sclerosis (MS). Momenta is partnered with Novartis' Sandoz...